Literature DB >> 12828091

Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis.

T Vyzantiadis1, S Theodoridou, O Giouleme, P Harsoulis, N Evgenidis, A Vyzantiadis.   

Abstract

BACKGROUND/AIMS: Insulin-like growth factor-I is an important anabolic polypeptide with various effects. The circulating insulin-like growth factor-I is mainly liver derived. The aim of this study was to determine insulin-like growth factor-I serum levels in patients with cirrhosis and to clarify their association with patients' clinical condition and the etiology of cirrhosis.
METHODOLOGY: Forty patients with liver cirrhosis were enrolled. Cirrhosis was in 22 cases induced by virus, in 10 due to primary biliary cause and in the rest 8 of alcoholic origin. The Child score index was found as A (n = 26), B (n = 9), C (n = 5). Twenty, age-matched healthy subjects, were used as a control group. Serum insulin-like growth factor-I was measured by an immunoradiometric assay in all subjects.
RESULTS: Serum insulin-like growth factor-I levels in liver cirrhosis were found very significantly lower than in healthy individuals (57.4 +/- 7.0 ng/mL vs. 198.8 +/- 16.3 ng/mL, p = 0.0000001). In liver cirrhosis insulin-like growth factor-I was negatively correlated with spleen enlargement (r = -0.46, p = 0.0031). Child B and C patients showed significantly reduced insulin-like growth factor-I levels in comparison to patients staged as Child A (28.9 +/- 3.0 ng/mL vs. 72.8 +/- 9.3 ng/mL, p = 0.0016). The comparison of 12 patients with viral induced cirrhosis (Child A) to 14 patients with non-viral cirrhosis, of the same clinical stage, showed non-significant difference (84.2 +/- 16 ng/mL vs. 63.1 +/- 10.3 ng/mL, p = 0.27).
CONCLUSIONS: Insulin-like growth factor-I synthesis is disturbed in liver cirrhosis and reflects the severity of the clinical stage. It represents a good marker of hepatic function. The etiology of cirrhosis does not seem to influence its levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828091

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  13 in total

1.  Effect of rapamycin on hepatic osteodystrophy in rats with portasystemic shunting.

Authors:  Schalk W van der Merwe; Maria M Conradie; Robert Bond; Brenda J Olivier; Elongo Fritz; Martin Nieuwoudt; Rhena Delport; Tomas Slavik; Gert Engelbrecht; Del Kahn; Enid G Shephard; Maritha J Kotze; Nico P de Villiers; Stephen Hough
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

2.  Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study.

Authors:  Wei-Wen Su; King-Teh Lee; Yao-Tsung Yeh; Maw-Soan Soon; Chao-Ling Wang; Ming-Lung Yu; Shen-Nien Wang
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

3.  Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis.

Authors:  Shi-Min Luo; Wei-Min Tan; Wei-Xiong Deng; Si-Min Zhuang; Jian-Wei Luo
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

4.  Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States.

Authors:  Shauna S Runchey; Edward J Boyko; George N Ioannou; Kristina M Utzschneider
Journal:  J Gastroenterol Hepatol       Date:  2014-03       Impact factor: 4.029

5.  Serum prolidase and IGF-1 as non-invasive markers of hepatic fibrosis during four different periods after bile-duct ligation in rats.

Authors:  Orhan Tarçin; Nursal Gedik; Berna Karakoyun; Veysel Tahan; Gagan Sood; Ciğdem Celikel; Nurdan Tözün
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

6.  Effects of parenteral nutrition with and without GH on the GH/IGF-1 axis after hepatectomy in hepatocellular carcinoma with liver cirrhosis.

Authors:  Jie Cao; Shimin Luo; Lijian Liang; Jiaming Lai; Shanming Chen
Journal:  Front Med China       Date:  2007-07-01

7.  Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis.

Authors:  Yun-Lin Wu; Jing Ye; Shu Zhang; Jie Zhong; Rong-Ping Xi
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

8.  Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C.

Authors:  Vicente Lorenzo-Zúñiga; Ramon Bartolí; Helena Masnou; Silvia Montoliu; Rosa Ma Morillas; Ramon Planas
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

9.  A survey of correlation between insulin-like growth factor-I (igf-I) levels and severity of liver cirrhosis.

Authors:  Asghar Khoshnood; Mohsen Nasiri Toosi; Mohammad Jafar Faravash; Alireza Esteghamati; Hosein Froutan; Hadi Ghofrani; Mohammad Kalani; Arash Miroliaee; Ahmad Abdollahi; Andrabi Yasir
Journal:  Hepat Mon       Date:  2013-02-23       Impact factor: 0.660

10.  Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C.

Authors:  Agnieszka Adamek; Aldona Kasprzak; Agnieszka Seraszek; Hanna Mikoś; Aleksandra Bura; Iwona Mozer-Lisewska
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.